Crossmark

Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC

Published Online: 2020-09-18

Published Print: 2020-12

Authors

Asakura, Hidesaku

Ogawa, Haruhiko
License Information

Text and Data Mining valid from 2020-09-18

Version of Record valid from 2020-09-18
More Information

Article History

Received: 21 May 2020

Accepted: 10 September 2020

First Online: 18 September 2020

Ethics approval and consent to participate

: N/A

: N/A

: None.

Document is current